Cancers, Free Full-Text

Urinary cytology is a useful, essential diagnostic method in routine urological clinical practice. Liquid-based cytology (LBC) for urothelial carcinoma screening is commonly used in the routine clinical cytodiagnosis because of its high cellular yields. Since conventional screening processes by cytoscreeners and cytopathologists using microscopes is limited in terms of human resources, it is important to integrate new deep learning methods that can automatically and rapidly diagnose a large amount of specimens without delay. The goal of this study was to investigate the use of deep learning models for the classification of urine LBC whole-slide images (WSIs) into neoplastic and non-neoplastic (negative). We trained deep learning models using 786 WSIs by transfer learning, fully supervised, and weakly supervised learning approaches. We evaluated the trained models on two test sets, one of which was representative of the clinical distribution of neoplastic cases, with a combined total of 750 WSIs, achieving an area under the curve for diagnosis in the range of 0.984–0.990 by the best model, demonstrating the promising potential use of our model for aiding urine cytodiagnostic processes.

Cancers, Free Full-Text

Epigenetic regulation during cancer transitions across 11 tumour types

Remission, cancer-free, no evidence of disease: What's the difference?

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries - Bray - 2018 - CA: A Cancer Journal for Clinicians - Wiley Online Library

Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry - The Lancet Public Health